Literature DB >> 26776507

Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.

Patrick J Grohar1, Suntae Kim2, Guillermo O Rangel Rivera3, Nirmalya Sen2, Sara Haddock2, Matt L Harlow4, Nichole K Maloney5, Jack Zhu6, Maura O'Neill7, Tamara L Jones2, Konrad Huppi2, Magdalena Grandin2, Kristen Gehlhaus2, Carleen A Klumpp-Thomas8, Eugen Buehler8, Lee J Helman9, Scott E Martin8, Natasha J Caplen10.   

Abstract

Ewing sarcoma cells depend on the EWS-FLI1 fusion transcription factor for cell survival. Using an assay of EWS-FLI1 activity and genome-wide RNAi screening, we have identified proteins required for the processing of the EWS-FLI1 pre-mRNA. We show that Ewing sarcoma cells harboring a genomic breakpoint that retains exon 8 of EWSR1 require the RNA-binding protein HNRNPH1 to express in-frame EWS-FLI1. We also demonstrate the sensitivity of EWS-FLI1 fusion transcripts to the loss of function of the U2 snRNP component, SF3B1. Disrupted splicing of the EWS-FLI1 transcript alters EWS-FLI1 protein expression and EWS-FLI1-driven expression. Our results show that the processing of the EWS-FLI1 fusion RNA is a potentially targetable vulnerability in Ewing sarcoma cells.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26776507      PMCID: PMC4755295          DOI: 10.1016/j.celrep.2015.12.063

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  37 in total

1.  Determination of the RNA binding specificity of the heterogeneous nuclear ribonucleoprotein (hnRNP) H/H'/F/2H9 family.

Authors:  M Caputi; A M Zahler
Journal:  J Biol Chem       Date:  2001-09-24       Impact factor: 5.157

2.  Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours.

Authors:  O Delattre; J Zucman; B Plougastel; C Desmaze; T Melot; M Peter; H Kovar; I Joubert; P de Jong; G Rouleau
Journal:  Nature       Date:  1992-09-10       Impact factor: 49.962

3.  EWS-FLI1 utilizes divergent chromatin remodeling mechanisms to directly activate or repress enhancer elements in Ewing sarcoma.

Authors:  Nicolò Riggi; Birgit Knoechel; Shawn M Gillespie; Bradley E Bernstein; Miguel N Rivera; Esther Rheinbay; Gaylor Boulay; Mario L Suvà; Nikki E Rossetti; Wannaporn E Boonseng; Ozgur Oksuz; Edward B Cook; Aurélie Formey; Anoop Patel; Melissa Gymrek; Vishal Thapar; Vikram Deshpande; David T Ting; Francis J Hornicek; G Petur Nielsen; Ivan Stamenkovic; Martin J Aryee
Journal:  Cancer Cell       Date:  2014-10-30       Impact factor: 31.743

4.  The genomic landscape of pediatric Ewing sarcoma.

Authors:  Brian D Crompton; Chip Stewart; Amaro Taylor-Weiner; Gabriela Alexe; Kyle C Kurek; Monica L Calicchio; Adam Kiezun; Scott L Carter; Sachet A Shukla; Swapnil S Mehta; Aaron R Thorner; Carmen de Torres; Cinzia Lavarino; Mariona Suñol; Aaron McKenna; Andrey Sivachenko; Kristian Cibulskis; Michael S Lawrence; Petar Stojanov; Mara Rosenberg; Lauren Ambrogio; Daniel Auclair; Sara Seepo; Brendan Blumenstiel; Matthew DeFelice; Ivan Imaz-Rosshandler; Angela Schwarz-Cruz Y Celis; Miguel N Rivera; Carlos Rodriguez-Galindo; Mark D Fleming; Todd R Golub; Gad Getz; Jaume Mora; Kimberly Stegmaier
Journal:  Cancer Discov       Date:  2014-09-03       Impact factor: 39.397

5.  A phase I, open-label, single-arm, dose-escalation study of E7107, a precursor messenger ribonucleic acid (pre-mRNA) splicesome inhibitor administered intravenously on days 1 and 8 every 21 days to patients with solid tumors.

Authors:  D S Hong; R Kurzrock; A Naing; J J Wheler; G S Falchook; J S Schiffman; N Faulkner; M J Pilat; J O'Brien; P LoRusso
Journal:  Invest New Drugs       Date:  2013-11-22       Impact factor: 3.850

6.  Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints.

Authors:  J Zucman; O Delattre; C Desmaze; B Plougastel; I Joubert; T Melot; M Peter; P De Jong; G Rouleau; A Aurias
Journal:  Genes Chromosomes Cancer       Date:  1992-11       Impact factor: 5.006

7.  Phase I pharmacokinetic and pharmacodynamic study of the first-in-class spliceosome inhibitor E7107 in patients with advanced solid tumors.

Authors:  Ferry A L M Eskens; Francisco J Ramos; Herman Burger; James P O'Brien; Adelaida Piera; Maja J A de Jonge; Yoshiharu Mizui; Erik A C Wiemer; Maria Josepa Carreras; José Baselga; Josep Tabernero
Journal:  Clin Cancer Res       Date:  2013-08-27       Impact factor: 12.531

Review 8.  Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.

Authors:  Heinrich Kovar
Journal:  Expert Opin Ther Targets       Date:  2014-08-27       Impact factor: 6.902

9.  Oncogenic ETS fusions deregulate E2F3 target genes in Ewing sarcoma and prostate cancer.

Authors:  Sven Bilke; Raphaela Schwentner; Fan Yang; Maximilian Kauer; Gunhild Jug; Robert L Walker; Sean Davis; Yuelin J Zhu; Marbin Pineda; Paul S Meltzer; Heinrich Kovar
Journal:  Genome Res       Date:  2013-08-12       Impact factor: 9.043

10.  The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.

Authors:  Andrew S Brohl; David A Solomon; Wendy Chang; Jianjun Wang; Young Song; Sivasish Sindiri; Rajesh Patidar; Laura Hurd; Li Chen; Jack F Shern; Hongling Liao; Xinyu Wen; Julia Gerard; Jung-Sik Kim; Jose Antonio Lopez Guerrero; Isidro Machado; Daniel H Wai; Piero Picci; Timothy Triche; Andrew E Horvai; Markku Miettinen; Jun S Wei; Daniel Catchpool; Antonio Llombart-Bosch; Todd Waldman; Javed Khan
Journal:  PLoS Genet       Date:  2014-07-10       Impact factor: 5.917

View more
  17 in total

1.  HNRNPH1 is required for rhabdomyosarcoma cell growth and survival.

Authors:  Yanfeng Li; Jesse Bakke; David Finkelstein; Hu Zeng; Jing Wu; Taosheng Chen
Journal:  Oncogenesis       Date:  2018-01-24       Impact factor: 7.485

Review 2.  RNA-binding proteins of COSMIC importance in cancer.

Authors:  Peter S Choi; Andrei Thomas-Tikhonenko
Journal:  J Clin Invest       Date:  2021-09-15       Impact factor: 19.456

3.  HNRNPH1 destabilizes the G-quadruplex structures formed by G-rich RNA sequences that regulate the alternative splicing of an oncogenic fusion transcript.

Authors:  Tam Vo; Tayvia Brownmiller; Katherine Hall; Tamara L Jones; Sulbha Choudhari; Ioannis Grammatikakis; Katelyn R Ludwig; Natasha J Caplen
Journal:  Nucleic Acids Res       Date:  2022-06-24       Impact factor: 19.160

Review 4.  Epigenetic and Transcriptional Signaling in Ewing Sarcoma-Disease Etiology and Therapeutic Opportunities.

Authors:  Mingli Li; Chun-Wei Chen
Journal:  Biomedicines       Date:  2022-06-05

Review 5.  Biology of the mRNA Splicing Machinery and Its Dysregulation in Cancer Providing Therapeutic Opportunities.

Authors:  Maxime Blijlevens; Jing Li; Victor W van Beusechem
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

6.  CPSF3-dependent pre-mRNA processing as a druggable node in AML and Ewing's sarcoma.

Authors:  Nathan T Ross; Felix Lohmann; Rohan E J Beckwith; Seth Carbonneau; Aleem Fazal; Wilhelm A Weihofen; Scott Gleim; Michael Salcius; Frederic Sigoillot; Martin Henault; Sarah H Carl; Juan B Rodríguez-Molina; Howard R Miller; Scott M Brittain; Jason Murphy; Mark Zambrowski; Geoffrey Boynton; Yuan Wang; Aye Chen; Gregory J Molind; Johannes H Wilbertz; Caroline G Artus-Revel; Min Jia; Favour A Akinjiyan; Jonathan Turner; Judith Knehr; Walter Carbone; Sven Schuierer; John S Reece-Hoyes; Kevin Xie; Chitra Saran; Eric T Williams; Guglielmo Roma; Matt Spencer; Jeremy Jenkins; Elizabeth L George; Jason R Thomas; Gregory Michaud; Markus Schirle; John Tallarico; Lori A Passmore; Jeffrey A Chao
Journal:  Nat Chem Biol       Date:  2019-12-09       Impact factor: 15.040

7.  Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma.

Authors:  Baisheng Yuan; Wei Ji; Haipeng Xia; Jianmin Li
Journal:  Mol Med Rep       Date:  2018-01-10       Impact factor: 2.952

8.  EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis.

Authors:  Nirmalya Sen; Allison M Cross; Philip L Lorenzi; Javed Khan; Berkley E Gryder; Suntae Kim; Natasha J Caplen
Journal:  Mol Carcinog       Date:  2018-06-19       Impact factor: 4.784

9.  Identification of the Gene Expression Rules That Define the Subtypes in Glioma.

Authors:  Yu-Dong Cai; Shiqi Zhang; Yu-Hang Zhang; Xiaoyong Pan; KaiYan Feng; Lei Chen; Tao Huang; Xiangyin Kong
Journal:  J Clin Med       Date:  2018-10-13       Impact factor: 4.241

10.  HNRNPH1-stabilized LINC00662 promotes ovarian cancer progression by activating the GRP78/p38 pathway.

Authors:  Yong Wu; Qinhao Guo; Xingzhu Ju; Zhixiang Hu; Lingfang Xia; Yu Deng; Ping Zhao; Meng Zhang; Yang Shao; Shenglin Huang; Xianghuo He; Hao Wen; Xiaohua Wu
Journal:  Oncogene       Date:  2021-06-19       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.